It is generally agreed that estrogens, and possibly androgens, are important in the etiology of breast cancer, but no consensus exists as to the precise estrogenic or 587-592 (1997) 
administration of antiestrogenic drugs, achieves the opposite effect (2, 3) . Substantial indirect evidence (4, 5) supports an etiologic role for estrogens in human breast cancer. For example, it has long been known that reproductive factors, such as delayed age at first full-term birth, increase a woman's risk for breast cancer, and that bilateral oophorectomy at a young age confers lasting protection against breast cancer (6) . The hormonal environment typical of premenopausal women, characterized by high levels of estradiol, progesterone, and gonadotropins, has been suggested (7) as the key to understanding why, in all populations, the incidence of breast cancer increases much more steeply among premenopausal women than among postmenopausal women (8, 9) .
Epidemiological research seeking direct evidence on the role of endogenous estrogens in breast cancer has produced conflicting and disappointing results (10) . In the late 1960s and 1970s, a number of hospital-based case-control studies of the relationship between urinary and circulating estrogens and breast cancer (11) (12) (13) (14) (15) (16) (17) ) generated enthusiasm and were followed by a wave of similar efforts (7) , most notably at the Harvard School of Public Health (12, (18) (19) (20) (21) . Such efforts produced inconsistent results. Most reports found no association (22) (23) (24) , although quite a few observed a modest, positive relationship with estradiol (13, 21, (25) (26) (27) (28) (29) (30) .
Renewed expectations followed the 1981 publication of a report by Siiteri and colleagues (31) suggesting that only the free and albumin-bound fractions of estradiol, rather that the fraction bound to sex hormone-binding globulin (SHBG), are relevant to breast cancer. The hypothesis was based on observations that 35 to 65% of estradiol and 50 to 75% of testosterone circulate bind to SHBG (a glycoprotein secreted by the liver), from which they dissociate very slowly (32) . Approximately 0.5 to 2% of the steroids circulate unbound (free) and the rest bind to albumin. The prevailing opinion concerning the role of SHBG is that binding reduces the availability of estradiol to the cells and that the free hormone (including the fraction that continuously dissociates from binding with albumin) diffuses freely into the cytoplasm and thus is immediately available for biologic action (33).
Siiteri's initial paper (31) reporting that free estradiol was elevated in postmenopausal breast cancer was followed by a number of similar case-control studies (21, 26, 30, (34) (35) (36) (37) (38) (39) (40) (41) (42) . With some exceptions, (36, 39, 42) these studies appeared to confirm Siiteri's initial observations, but their overall impact was modest when it became evident that the observed association was not of sufficient strength to explain much of breast cancer epidemiology. Enthusiasm for the hypothesis was further dampened by a number of case-control studies of SHBG, some reporting weaker than predicted protective associations (34, 40, 43, 44) , and many failing to observe any (21, 29, 30, 39, 42, 45) .
To date, only a handful of investigators have examined the role of endogenous estrogens prospectively. In the mid-1950s, Bulbrook and colleagues (46) pioneered the effort by initiating a prospective cohort study of 5000 women in the British island of Guernsey, which eventually led to the identification of 27 cases of breast cancer. Initially, they reported no differences in Environmental Health Perspectives * Vol 105, Supplement 3 -April 997 04"mt urinary estrogens between cases and noncases, but later showed that serum levels of free estradiol were considerably higher among the cases than the controls in the same population (38) . More recently, Wysowski and colleagues (47) conducted a case-control study nested in a prospective cohort study of 11,009 women in Washington County, Maryland, which was assembled in 1974 (48) . In a small study group that included 17 (53) . Soon afterward, Berrino and colleagues (54) reported the results of a prospective cohort study in northern Italy (the Ormoni e Dieta nell'Eziologia dei Tumori study), with a design similar to the New York Women's Health Study Cohort. In a case-control study nested in this cohort of 10,000 (24 breast cancer cases out of 4040 postmenopausal subjects), they reported a 5.5-fold increase in breast cancer risk in the upper tertile of serum estradiol, as well as a strong protective effect of SHBG, and a strong association with serum testosterone. Dorgan et al. (55) reported the result of a case-control study ( 
Issues in Study Design
Traditional Case-Control Studies
The majority of early studies that assessed the association between endogenous estrogens in blood and urine and the risk of breast cancer were case-control studies in which breast cancer cases were identified among patients attending medical facilities for diagnosis or treatment. In this study design, assessment of exposure to endogenous hormones is performed among the cases on biological specimens (e.g., peripheral venous blood, urine, or salivaJ that are obtained at the time, or sometimes long after, breast cancer has become clinically manifest. Because sampling occurs after the onset of clinical disease, there is uncertainty as to whether exposure truly precedes disease or, in other words, whether exposure and disease occur in the correct temporal sequence-one of the most fundamental prerequisites of observational studies. Thus, the results of these studies are meaningful only if it can be reasonably assumed that the presence of the disease at the clinical stage does not influence hormonal measurements and that the hormonal measurements provide an unbiased and accurate reflection of hormone levels during an appropriate time in the natural history of the disease.
It is not known whether biochemical measurements conducted on samples obtained after clinical diagnosis reflect longterm endogenous hormone levels. However, it is clear that under normal conditions, blood hormone levels are subject to fluctuations, such as circadian, menstrual, and seasonal cycles, and are influenced by physical activity, diet, emotions, trauma, and disease. The possibility of distortion on relative risk estimates consequent to the misclassification of exposure induced by these fluctuations has been recognized. Attempts 
Prospective Cohort Studies
The alternative approach used to assess the relationship between endogenous hormones and breast cancer is conduction of case-control studies nested within a prospective cohort. In this type of study, the assessment of exposure is performed on biological samples collected from all or most of the cohort members prior to clinical disease onset and stored for future use (Figure 1 ). Rather than measuring biochemical markers on specimens from all members of the cohort, which would be prohibitively expensive, only breast cancer cases and controls drawn from among the nondisease members of the cohort are considered. This approach provides unbiased results and only a negligible loss of statistical power, as compared to a full cohort analysis (57, 58 A further advantage of the nested case-control approach over traditional hospital-based case-control studies is the need to bank biological specimens from the whole cohort. Even though the bank is organized to fulfill the requirements of specific hypotheses, ultimately, only a very small fraction of the total number of specimens banked will be used to test the study's original hypotheses. Most of the remainder will be available for additional investigations. Thus, prospective cohort studies with biological banking provide resources of great efficiency that would remain available for scientific inquiries long after the completion of the initial study. This unique advantage, however, must be openly recognized at the very beginning so that the cohort and its biological bank are designed to take full advantage of it. The design of such studies should take into account issues such as a) obtaining appropriate informed consent from individuals for future reference, b) the timing of sampling in relation to physiological factors (e.g., pregnancy, ovariectomy, menstrual cycle, menopause) and external events (e.g., recent meals, medication use, recreational drug use, physical activity), c) the tight standardization of procedures for the collection, preparation, and handling of biological specimens, and d) considerations for long-term storage of specimens, such as storage temperature, type of specimens in storage, volume and number of aliquots, defrosting, and the likelihood of accidents. All these factors may significantly affect the efficiency of prospective cohort studies in conducting future studies on many disease outcomes. They may mask differences in biomarker levels between individuals or within the same individual at different points in time, or may affect the ability to control for confounding, or to assess effect modification (e.g., through markers of genetic susceptibility).
Future Perspectives
Emerging epidemiological evidence shows that increased blood levels of major sex steroid hormones (androgens and estrogens), play an important role in the etiology of breast cancer in postmenopausal women. Recent data also show that women with the thickest bone density, which can be taken as a surrogate for cumulative, lifetime exposure to endogenous hormones, experience a 3-fold increased risk of breast cancer as compared to women with thin bones (59) . These findings complement and expand the observations based on direct measurement of endogenous hormones and are consistent with data relating reduced risk of breast and endometrial cancers to the occurrence of bone fractures in the forearm (60) and hip (61, 62) .
Increased levels of circulating hormones may be the result of an overall increase in ovarian or adrenal secretion occurring or persisting after menopause. In high-risk populations, women tend to experience menarche at a younger age, menopause at an older age and reach higher adult body height and weight than in low-risk populations (63, 64) . These factors, which have been associated with increased breast cancer risk in all populations (65) A number of observations, including large differences in incidence rates between populations (67) and studies of women migrating from low-risk to high-risk areas (68) (69) (70) suggest that diet is probably the single most important factor in breast cancer etiology. This may hold true even though analytical epidemiological studies have failed to reveal specific patterns of nutrition that are associated with the disease (71) . The lack of a convincing association between diet and breast cancer can be ascribed in large part to methodological problems, e.g., the inadequacy of dietary assessment and the difficulty of measuring small differences among individuals living in the same geographical area who share similar nutritional habits (72 The new studies will not be rapid or easy to conduct. The best investment of our modest resources during the next decade would be to elucidate the role of endogenous sex hormones in breast cancer. Such an investment of time is necessary and unavoidable; it would be difficult, if not impossible, to implement effective measures for the primary prevention of breast cancer without a sufficient epidemiological knowledge of nutritionally induced hormonal imbalances. Even though time requirements would be substantial, this effort would create tremendous opportunities for additional research, e.g., exploration of the association of breast cancer with exposure to xenobiotics in the environment or in the diet, the role of specific nutritional factors measurable through biomarkers, and other types of chronic diseases affecting women.
